Summit Therapeutics Inc. (SMMT)
NASDAQ
15.47
-0.08 (-0.51%)
Delayed Data
Oct 23, 2026, 01:30 PM
Day's Range
15.0715.55
52 wk Range
12.0729.23
Financial Statements - SMMT - Summit Therapeutics Inc.
Revenue
0
Net Income
-1.07B▼ 387.8%
EBITDA
-1.09B▼ 454.3%
Free Cash Flow
-323.58M▼ 127.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 705K | 1.80M | 860K |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -1.09B | -210.96M | -88.77M | -63.57M | -86.17M | -52.30M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 14.83M | -15.10M | -520.13M | -12.27M | -2.17M | -325K |
| Pre Tax Income | -1.07B | -221.28M | -614.92M | -78.78M | -88.60M | -52.91M |
| Income Tax | - | - | - | - | 0 | -213K |
| Net Income | -1.07B | -221.28M | -614.92M | -78.78M | -88.60M | -52.69M |
| EPS Basic | -1.44 | -0.31 | -0.99 | -0.41 | -0.96 | -0.76 |
| EPS Diluted | -1.44 | -0.31 | -0.99 | -0.41 | -0.96 | -0.76 |
| Basic Shares Outstanding | 747.70M | 718.54M | 619.64M | 193.33M | 92.29M | 69.33M |
| Diluted Shares Outstanding | 747.70M | 718.54M | 619.64M | 193.33M | 92.29M | 69.33M |
| Ebit | -1.07B | -212.60M | -598.46M | -74.38M | -88.36M | -52.65M |
| Ebitda | -1.09B | -197.40M | -76.53M | -59.29M | -83.77M | -49.84M |
| Net Income Continuous Operations | -1.07B | -221.31M | -614.92M | -78.78M | -88.60M | -52.69M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
